Owing to the revision of the TPA and the corresponding implementing ordinances (Therapeutic Products Ordinance Package IV), Swissmedic has adapted the specification documents and forms for authorisation applications.
Like the previously analysed products with valsartan, products with losartan, olmesartan and candesartan that have been investigated do not contain elevated NDMA levels.
Swissmedic is the Swiss authority responsible for the authorisation and supervision of therapeutic products. Swissmedic's activities are based on the Law on Therapeutic Products.
What is a medical device? How do medical devices come onto the market? How do you recognise a medical device? Based on examples, our videos answer these and a number of other questions.
